Tags

Type your tag names separated by a space and hit enter

Metabolic effects of long-acting somatostatin analogue (sandostatin) in type I diabetic patients on conventional therapy.
Diabetes. 1989 Jun; 38(6):704-9.D

Abstract

We evaluated the effectiveness of a more potent and longer-acting somatostatin analogue (SMS 201-995) as an adjunct to insulin therapy, in a double-blind placebo-controlled randomized study of 26 C-peptide-negative type I (insulin-dependent) diabetic patients (20 women, 6 men, aged 22-40 yr) on their conventional drug regimens for 12 wk. Eight patients received a low dose (10 micrograms) of the analogue, 9 received a high dose (50 micrograms) of the analogue, and 9 received placebo subcutaneously before breakfast and dinner. Twenty-four-hour serum glucose, free insulin, plasma growth hormone (GH), and glucagon profiles were obtained before and during treatment at 4-wk intervals. The mean age, duration of diabetes, daily insulin dose, and body weight were not significantly different among the groups. The mean weekly capillary blood glucose values and exogenous insulin requirements were not changed by the SMS 201-995 therapy. Mean glycosylated hemoglobin A1 levels were unchanged in both the analogue- and placebo-treated groups at wk 12. Basal and postprandial glucose, free insulin, GH, and glucagon profiles were not influenced by the SMS 201-995 therapy throughout the study. Nocturnal glucose turnover rates (D-[3-3H]glucose technique) remained unaltered by the analogue therapy. Dose-dependent gastrointestinal (GI) adverse effects (e.g., diarrhea) were documented in the analogue-treated patients. Visual acuity and fundic photomicrographs of our patients were not changed by the analogue therapy. In conclusion, the prominent adverse GI effects our patients experienced preclude the use of larger doses of the analogue that may be necessary to suppress GH and glucagon and improve glucose control in type I diabetic patients.

Authors+Show Affiliations

Department of Internal Medicine, Ohio State University Hospitals, Columbus.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

2656340

Citation

Osei, K, et al. "Metabolic Effects of Long-acting Somatostatin Analogue (sandostatin) in Type I Diabetic Patients On Conventional Therapy." Diabetes, vol. 38, no. 6, 1989, pp. 704-9.
Osei K, O'Dorisio TM, Malarkey WB, et al. Metabolic effects of long-acting somatostatin analogue (sandostatin) in type I diabetic patients on conventional therapy. Diabetes. 1989;38(6):704-9.
Osei, K., O'Dorisio, T. M., Malarkey, W. B., Craig, E. L., & Cataland, S. (1989). Metabolic effects of long-acting somatostatin analogue (sandostatin) in type I diabetic patients on conventional therapy. Diabetes, 38(6), 704-9.
Osei K, et al. Metabolic Effects of Long-acting Somatostatin Analogue (sandostatin) in Type I Diabetic Patients On Conventional Therapy. Diabetes. 1989;38(6):704-9. PubMed PMID: 2656340.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Metabolic effects of long-acting somatostatin analogue (sandostatin) in type I diabetic patients on conventional therapy. AU - Osei,K, AU - O'Dorisio,T M, AU - Malarkey,W B, AU - Craig,E L, AU - Cataland,S, PY - 1989/6/1/pubmed PY - 1989/6/1/medline PY - 1989/6/1/entrez SP - 704 EP - 9 JF - Diabetes JO - Diabetes VL - 38 IS - 6 N2 - We evaluated the effectiveness of a more potent and longer-acting somatostatin analogue (SMS 201-995) as an adjunct to insulin therapy, in a double-blind placebo-controlled randomized study of 26 C-peptide-negative type I (insulin-dependent) diabetic patients (20 women, 6 men, aged 22-40 yr) on their conventional drug regimens for 12 wk. Eight patients received a low dose (10 micrograms) of the analogue, 9 received a high dose (50 micrograms) of the analogue, and 9 received placebo subcutaneously before breakfast and dinner. Twenty-four-hour serum glucose, free insulin, plasma growth hormone (GH), and glucagon profiles were obtained before and during treatment at 4-wk intervals. The mean age, duration of diabetes, daily insulin dose, and body weight were not significantly different among the groups. The mean weekly capillary blood glucose values and exogenous insulin requirements were not changed by the SMS 201-995 therapy. Mean glycosylated hemoglobin A1 levels were unchanged in both the analogue- and placebo-treated groups at wk 12. Basal and postprandial glucose, free insulin, GH, and glucagon profiles were not influenced by the SMS 201-995 therapy throughout the study. Nocturnal glucose turnover rates (D-[3-3H]glucose technique) remained unaltered by the analogue therapy. Dose-dependent gastrointestinal (GI) adverse effects (e.g., diarrhea) were documented in the analogue-treated patients. Visual acuity and fundic photomicrographs of our patients were not changed by the analogue therapy. In conclusion, the prominent adverse GI effects our patients experienced preclude the use of larger doses of the analogue that may be necessary to suppress GH and glucagon and improve glucose control in type I diabetic patients. SN - 0012-1797 UR - https://www.unboundmedicine.com/medline/citation/2656340/Metabolic_effects_of_long_acting_somatostatin_analogue__sandostatin__in_type_I_diabetic_patients_on_conventional_therapy_ DB - PRIME DP - Unbound Medicine ER -